US · 1 entry · 1 publication
Relay Therapeutics, Inc.
No entry states a stance.
Free during launch: log in or sign up with your email to see it.
Sign up freeSubstack · Pierce Capital Research · Steve Wagner
Taking a Look at Lemonade (LMND) & Relay Therapeutics (RLAY) Earnings Results.
Since publication RLAY +457.5% α +437.1 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.